StonvexLoading…
StonvexStonvexStonvexCore line items from TNK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $951.80M | $1.23B | $1.47B | $1.18B |
Operating Income | $309.10M | $380.14M | $546.76M | $263.82M |
Net Income | $351.19M | $403.67M | $519.89M | $235.43M |
EPS (Diluted) | $10.10 | $11.63 | $15.04 | $6.87 |
Total Assets | $2.24B | $1.97B | $1.94B | $1.78B |
Total Liabilities | $198.06M | $217.42M | $391.51M | $713.65M |
Cash & Equivalents | $830.57M | $511.89M | $391.46M | $206.93M |
Free Cash Flow OCF − CapEx | $115.64M | $401.41M | $631.25M | $199.69M |
Shares Outstanding | 34.78M | 34.71M | 34.57M | 34.29M |